Logo image of VSTM

VERASTEM INC (VSTM) Stock Price, Quote, News and Overview

NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD

6.94  +0.25 (+3.74%)

Premarket: 7.15 +0.21 (+3.03%)

VSTM Quote, Performance and Key Statistics

VERASTEM INC

NASDAQ:VSTM (5/8/2025, 8:27:52 PM)

Premarket: 7.15 +0.21 (+3.03%)

6.94

+0.25 (+3.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High13.52
52 Week Low2.1
Market Cap357.34M
Shares51.49M
Float46.35M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO11-08 2011-11-08


VSTM short term performance overview.The bars show the price performance of VSTM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

VSTM long term performance overview.The bars show the price performance of VSTM in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of VSTM is 6.94 USD. In the past month the price increased by 31.44%. In the past year, price decreased by -41.43%.

VERASTEM INC / VSTM Daily stock chart

VSTM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 328.29B
AMGN AMGEN INC 13.1 146.27B
GILD GILEAD SCIENCES INC 12.68 122.21B
VRTX VERTEX PHARMACEUTICALS INC N/A 110.44B
REGN REGENERON PHARMACEUTICALS 12.36 59.13B
ARGX ARGENX SE - ADR 299.54 34.75B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.61B
ONC BEIGENE LTD-ADR 5.88 25.43B
BNTX BIONTECH SE-ADR N/A 22.78B
NTRA NATERA INC N/A 22.10B
SMMT SUMMIT THERAPEUTICS INC N/A 18.31B
BIIB BIOGEN INC 7.48 17.35B

About VSTM

Company Profile

VSTM logo image Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Company Info

VERASTEM INC

117 Kendrick Street, Suite 500

Needham MASSACHUSETTS 02494 US

CEO: Brian M. Stuglik

Employees: 78

VSTM Company Website

VSTM Investor Relations

Phone: 17812924200

VERASTEM INC / VSTM FAQ

What is the stock price of VERASTEM INC today?

The current stock price of VSTM is 6.94 USD. The price increased by 3.74% in the last trading session.


What is the ticker symbol for VERASTEM INC stock?

The exchange symbol of VERASTEM INC is VSTM and it is listed on the Nasdaq exchange.


On which exchange is VSTM stock listed?

VSTM stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERASTEM INC stock?

15 analysts have analysed VSTM and the average price target is 13.64 USD. This implies a price increase of 96.58% is expected in the next year compared to the current price of 6.94. Check the VERASTEM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERASTEM INC worth?

VERASTEM INC (VSTM) has a market capitalization of 357.34M USD. This makes VSTM a Small Cap stock.


How many employees does VERASTEM INC have?

VERASTEM INC (VSTM) currently has 78 employees.


What are the support and resistance levels for VERASTEM INC (VSTM) stock?

VERASTEM INC (VSTM) has a support level at 6.52 and a resistance level at 7.51. Check the full technical report for a detailed analysis of VSTM support and resistance levels.


Is VERASTEM INC (VSTM) expected to grow?

The Revenue of VERASTEM INC (VSTM) is expected to grow by 17.95% in the next year. Check the estimates tab for more information on the VSTM EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERASTEM INC (VSTM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERASTEM INC (VSTM) stock pay dividends?

VSTM does not pay a dividend.


When does VERASTEM INC (VSTM) report earnings?

VERASTEM INC (VSTM) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of VERASTEM INC (VSTM)?

VERASTEM INC (VSTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.5).


What is the Short Interest ratio of VERASTEM INC (VSTM) stock?

The outstanding short interest for VERASTEM INC (VSTM) is 19.02% of its float. Check the ownership tab for more information on the VSTM short interest.


VSTM Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is a bad performer in the overall market: 70.23% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VSTM Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to VSTM. VSTM may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VSTM Financial Highlights

Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.5. The EPS increased by 14.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -128.66%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-30.39%
Sales Q2Q%N/A
EPS 1Y (TTM)14.63%
Revenue 1Y (TTM)N/A

VSTM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to VSTM. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 30.11% and a revenue growth 17.95% for VSTM


Ownership
Inst Owners65.43%
Ins Owners0.96%
Short Float %19.02%
Short Ratio9.57
Analysts
Analysts85.33
Price Target13.64 (96.54%)
EPS Next Y30.11%
Revenue Next Year17.95%